Significant milestone at our START Madrid FJD location! – The START Center for Cancer Research
The START Center for Cancer Research shared on LinkedIn:
“We’re thrilled to announce a significant milestone at our START Madrid FJD location! Today, we successfully dosed the first global patient in the groundbreaking Phase I study of NILK-2301, a pioneering therapy developed by Light Chain Bioscience | Novimmune SA in partnership with LamKap Bio Group.
Led by our Principal Investigator, Dr. Victor Moreno of START Madrid FJD, this first-in-human trial marks a pivotal moment in our relentless pursuit of innovative cancer treatments. NILK-2301, a bispecific antibody designed to drive T-cell retargeting to tumor cells, holds immense promise in the fight against solid cancers. With its unique mechanism of action, targeting CEACAM5 and CD3, NILK-2301 represents a new frontier in cancer immunotherapy.
Our collaboration with Light Chain Biosciences, and the incredible work of our START Madrid FJD team, underscores START’s commitment to advancing transformative therapies for patients worldwide.
Stay tuned as we continue to push the boundaries of cancer research and bring hope to those in need.”
Read further.
Source: The START Center for Cancer Research/LinkedIn